Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EC-18 in altering the severity and course of oral mucositis in patients being treated with concomitant chemoradiation therapy for cancers of the mouth, oropharynx, hypopharynx, and nasopharynx
To determine the effects of oral investigational medication EC-18 on oral mucositis in patients being treated with chemotherapy and radiation therapy for squamous cell carcinoma of the oral cavity or oropharynx.
Squamous cell cancer of the head and neck (SCCHN)
Patients with diagnosis of squamous cell carcinoma of the head and neck who are 18 years of age and older. Patients must not have received prior chemotherapy or radiation therapy but plan to be treated this way.
18 - 100
Healthy Volunteers Needed
Duration of Participation
15 months, including screening and long-term follow-up.
Sr. Research Assistant
Oregon Health & Science University
Department of Radiation Medicine
Enzychem Lifescience Corporation